Miika Martikainen
Researcher at Department of Immunology, Genetics and Pathology; Research programme: Cancer Immunotherapy; Research group Magnus Essand
- E-mail:
- miika.martikainen@igp.uu.se
- Visiting address:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postal address:
- Rudbecklaboratoriet
751 85 UPPSALA
Publications
Recent publications
VLDLR mediates Semliki Forest virus neuroinvasion through the blood-cerebrospinal fluid barrier
Part of Nature Communications, 2024
- DOI for VLDLR mediates Semliki Forest virus neuroinvasion through the blood-cerebrospinal fluid barrier
- Download full text (pdf) of VLDLR mediates Semliki Forest virus neuroinvasion through the blood-cerebrospinal fluid barrier
Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma
Part of Cancer Cell, p. 1134-1151, 2023
- DOI for Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma
- Download full text (pdf) of Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma
Part of MOLECULAR THERAPY-ONCOLYTICS, p. 37-46, 2021
- DOI for IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma
- Download full text (pdf) of IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma
Part of Cell Death and Disease, 2020
- DOI for Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer
- Download full text (pdf) of Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer
Virus-Based Immunotherapy of Glioblastoma
Part of Cancers, 2019
- DOI for Virus-Based Immunotherapy of Glioblastoma
- Download full text (pdf) of Virus-Based Immunotherapy of Glioblastoma
All publications
Articles in journal
VLDLR mediates Semliki Forest virus neuroinvasion through the blood-cerebrospinal fluid barrier
Part of Nature Communications, 2024
- DOI for VLDLR mediates Semliki Forest virus neuroinvasion through the blood-cerebrospinal fluid barrier
- Download full text (pdf) of VLDLR mediates Semliki Forest virus neuroinvasion through the blood-cerebrospinal fluid barrier
Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma
Part of Cancer Cell, p. 1134-1151, 2023
- DOI for Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma
- Download full text (pdf) of Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma
Part of MOLECULAR THERAPY-ONCOLYTICS, p. 37-46, 2021
- DOI for IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma
- Download full text (pdf) of IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma
Part of Cell Death and Disease, 2020
- DOI for Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer
- Download full text (pdf) of Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer
Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins
Part of Viruses, 2017
- DOI for Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins
- Download full text (pdf) of Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins
Part of MOLECULAR THERAPY-ONCOLYTICS, p. 67-75, 2017
- DOI for Insertion of the Type-I IFN Decoy Receptor B18R in a miRNA-Tagged Semliki Forest Virus Improves Oncolytic Capacity but Results in Neurotoxicity
- Download full text (pdf) of Insertion of the Type-I IFN Decoy Receptor B18R in a miRNA-Tagged Semliki Forest Virus Improves Oncolytic Capacity but Results in Neurotoxicity
Part of Translational Oncology, p. 772-779, 2017
Part of British Journal of Cancer, p. 51-55, 2017